Yohimbine HCL is the synthetic version of Yohimbine extract from the yohimbe tree. Yohimbine HCL safer and results proven, due to its highly controlled dosages. 

Yohimbe (the tree and bark, and its subset yohimbine (the extract), are fat-burning compounds, primarily used to lose fat during short term fasting.

Yohimbine is found naturally occurring primarily as an alkaloid in the Pausinystalia yohimbe tree (sometimes referred to as Corynanthe yohimbe), and can be found in the plant known as Rauwolfia Serpentina,  as well as the Rauwolfia family of plants in general.

Yohimbine, as a molecule, is sometimes also referred to as aphordine, corynine, hydroaergotocin, and quebrachine.

Yohimbine is also an aphrodisiac and can aid erectile dysfunction in men only. This does not affect women. It is also a general stimulant and energy booster. 

Yohimbine works by increasing adrenaline levels in the body, as well as inhibiting a regulatory process in fat cells – mainly stubborn fat cell receptors, which normally suppresses fat burning.

The effects of yohimbine HCL are ineffective if taken with a high carbohydrate diet, which is why Y-HCL should be taken in a fasted state.

Recommended Dosage & Active Amounts

Dosages of 0.2mg/kg bodyweight have been successfully used to increase fat burning without significant implications on cardiovascular parameters like heart rate and blood pressure. This results in a dosage of:

• 14 mg for a 150lb person
• 18 mg for a 200lb person
• 22 mg for a 250lb person

Supplementation is most effective between meals or during short term fasting.

Caution should be exercised at higher body weight, since the cardiovascular system may not be prepared to handle the stimulation from Y-HCL. When supplementing Y-HCL for the first time, always start with a half-dose and assess tolerance before proceeding.

When pairing yohimbine with other stimulatory agents, half-dose both supplements and work up to the recommended dose cautiously, as two supplements can interact negatively.

Sleep

Y-HCL does not affect sleep.

Fat Mass and Obesity

Y-HCL is an antagonist (Inactivation) of the Alpha-2-Adrenergic receptors preserves fat burning effects mediated via other mechanisms, a negation of a suppressive effect that ultimately results in more lipolysis (fat burning)

Yohimbine acts upon the adrenergic receptor system of fat cells, which regulate thermogenesis. The beta-subunits of the adrenergic receptors (targets of ephedrine) can be seen as stimulatory for fat loss as they increase the activity of the enzyme Adenyl Cyclase and subsequently cAMP levels (mainly via the b1 and b2 subunits; with b3 being less active in humans). The alpha-subunits are more suppressive of fat metabolism, in which their activation reduces activity of Adenyl Cyclase and reduces cAMP levels (specifically alpha-2). Yohimbine is a selective alpha-2 adrenergic receptor antagonist (inactivator), which inhibits activation of the suppressive set of receptors and preserves Adenyl Cyclase activity and the effects mediated via the beta receptors.

Beyond that, yohimbine itself can potentially induce fat loss vicariously through the release of adrenaline; adrenaline itself is an activator of beta-adrenergic receptors.

One study has been conducted with Yohimbine in elite soccer players taking 10mg yohimbine twice a day (20mg total) for a period of 21 days noted that, after the diet was controlled for, that fat percentage was decreased from 9.3+/-1.1% to 7.1+/-2.2% (assessed via calipers), while placebo experienced a nonsignificant increase.

0.2mg/kg Yohimbine in otherwise healthy men appears to enhance the fat burning effects of endogenous noradrenaline, and appears to be more effective during periods of exercise and attenuated if given beta-blockers; another study noted this attenuation to be measured at 70%.

 

Caution Notice

• Y- HCL can cause extreme anxiety in individuals predisposed to anxiety. Yohimbine may trigger manic psychosis or suicidal episodes in people with bipolar disorder
• Yohimbine can interact with a large amount of neurological medications and should not be used in conjunction with these medication without consultation with a doctor.
• Y-HCL is not for pregnant women and those who are breastfeeding.

Yohimbine and Anxiety

If you are predisposed to anxiety, then taking Y-HCL may increase your chances of anxiety attacks.

One study that measured anxiety via EEG (using the frontal midline theta pulse as biomarker) noted that participants with less anxiety at baseline that recieving 15mg yohimbine did not influence anxiety as measured by either EEG or self-report, while those with higher baseline anxiety experienced an exacerbation of anxiety on both measures; general arousal was increased in both groups.

Stress and Panic

Due to effectively increasing noradrenaline, the neural side-effects of excess noradrenaline may result if too high a dose is taken; the most common are anxiety and panic disorders, with the later affecting susceptable persons.

This increase in anxiety may be a per se effect of yohimbine in excess, as 30mg yohimbine can induce anxiety acutely in otherwise healthy persons (assessed by the Visual Analogue Scale for Anxiety), opioid dependent persons, and in persons who are susceptable to panic attacks; where yohimbine may be able to induce panic attacks.

Do not take Y-HCL more than the recommended dosage. 

Supplement Burn It Down

Great News! Our fat burner Burn It Down will be launching soon! Join our exclusive group of people to be the first to know when it launches. And receive a early bird discount! Worldwide shipping available!

Burn It Down is a blend Y-HCL supplement (plus our secret extracts that include green tea and other) that targets stubborn fat cells directly. Y-HCL is results proven in burning stubborn fat in women (lower body) and men (back). Burn It Down priced at $55, and early bird discount at $45 for a 3 months supply – 90 capsules.

Enter your email below for the early birds Burn It Down discount and to know the date of release!

 

---

References:

1. Effect of the dietary supplement Meltdown on catecholamine secretion, markers of lipolysis, and metabolic rate in men and women: a randomized, placebo controlled, cross-over study.
2. Singh DK, Srivastava B, Sahu A. Spectrophotometric determination of Rauwolfia alkaloids: estimation of reserpine in pharmaceuticals. Anal Sci. (2004)
3. Cimolai N, Cimolai T. Yohimbine use for physical enhancement and its potential toxicity. J Diet Suppl. (2011)
4. Rockhold RW, Gross F. Yohimbine diastereoisomers: cardiovascular effects after central and peripheral application in the rat. Naunyn Schmiedebergs Arch Pharmacol. (1981)
5. Weitzell R, Tanaka T, Starke K. Pre- and postsynaptic effects of yohimbine stereoisomers on noradrenergic transmission in the pulmonary artery of the rabbit.Naunyn Schmiedebergs Arch Pharmacol. (1979)
6. Material Safety Data Sheet for Yohimbine hydrochloride.
7. Asker AF, Helal MA, Motawi MM. Light stability of some parenteral solutions of reserpine. Pharmazie. (1971)
8. Jamil N, et al. Studies on the photostability of reserpine in parenteral solutions. Pharmazie. (1983)
9. Strobl GR, et al. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. (1993)
10. Le Corre P, et al. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther. (2004)
11. Bharucha AE, et al. Relationship of cytochrome P450 pharmacogenetics to the effects of yohimbine on gastrointestinal transit and catecholamines in healthy subjects. Neurogastroenterol Motil. (2008)
12. Ozawa S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet. (2004)
13. Taouis M, et al. Mechanism of the lipid-mobilizing effect of alpha-2 adrenergic antagonists in the dog. J Pharmacol Exp Ther. (1988)
14. Szemeredi K, et al. Simultaneous measurement of plasma and brain extracellular fluid concentrations of catechols after yohimbine administration in rats. Brain Res. (1991)
15. Ehlert U, et al. Salivary alpha-amylase levels after yohimbine challenge in healthy men. J Clin Endocrinol Metab. (2006)
16. Meyerbroeker K, et al. Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial.Psychother Psychosom. (2012)
17. Hedner T, et al. Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. Eur J Clin Pharmacol. (1992)
18. Grossman E, et al. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. (1993)
19. Galitzky J, et al. Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers. Eur J Clin Pharmacol. (1990)
20. Berlan M, et al. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes. (1991)
21. Sturgill MG, et al. Yohimbine elimination in normal volunteers is characterized by both one- and two-compartment behavior. J Cardiovasc Pharmacol. (1997)
22. Mizuki Y, et al. Differential effects of noradrenergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog Neuropsychopharmacol Biol Psychiatry. (1996)
23. Kennedy SH, et al. Melatonin responses to clonidine and yohimbine challenges. J Psychiatry Neurosci. (1995)
24. Arnsten AF. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs. (2009)
25. Swanson CJ, et al. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology. (2006)
26. Gronier B. In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors. Eur Neuropsychopharmacol. (2011)
27. Roychowdhury S, et al. α₂- and β-adrenoceptors involvement in nortriptyline modulation of auditory sustained attention and impulsivity. Psychopharmacology (Berl). (2012)
28. Callahan MF, Beales M, Oltmans GA. Yohimbine and rauwolscine reduce food intake of genetically obese (obob) and lean mice. Pharmacol Biochem Behav. (1984)
29. Jonderko K, Kucio C. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. Aliment Pharmacol Ther. (1991)
30. Clark JT, Smith ER, Davidson JM. Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats. Neuroendocrinology. (1985)
31. Koskinen I, et al. Yohimbine and naloxone: effects on male rat sexual behavior. Physiol Behav. (1991)
32. Clark JT, Smith ER, Davidson JM. Enhancement of sexual motivation in male rats by yohimbine. Science. (1984)
33. Rodríguez-Manzo G, Fernández-Guasti A. Reversal of sexual exhaustion by serotonergic and noradrenergic agents. Behav Brain Res. (1994)
34. Clark JT, Smith ER, Davidson JM. Testosterone is not required for the enhancement of sexual motivation by yohimbine. Physiol Behav. (1985)
35. Travison TG, et al. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. (2006)
36. Guay AT, Jacobson J. Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido. J Sex Marital Ther. (2002)
37. Crespi F. Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety. J Neurosci Methods. (2009)
38. Charney DS, Heninger GR, Redmond DE Jr. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine.Life Sci. (1983)
39. Stine SM, et al. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry. (2002)
40. Gurguis GN, Vitton BJ, Uhde TW. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. (1997)
41. Sommer M, et al. Psychological and neuroendocrine responses to social stress and to the administration of the alpha-2-receptor antagonist, yohimbine, in highly trained endurance athletes in comparison to untrained healthy controls. Pharmacopsychiatry. (2011)
42. Rimmele U, et al. Trained men show lower cortisol, heart rate and psychological responses to psychosocial stress compared with untrained men.Psychoneuroendocrinology. (2007)
43. Cameron OG, et al. Effects of yohimbine on cerebral blood flow, symptoms, and physiological functions in humans. Psychosom Med. (2000)
44. Powers MB, et al. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord. (2009)
45. Gentili A, et al. Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. Eur J Clin Pharmacol. (1996)
46. Anderson KJ, Revelle W. Impulsivity and time of day: is rate of change in arousal a function of impulsivity. J Pers Soc Psychol. (1994)
47. Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev. (2006)
48. Brennan AR, Arnsten AF. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci. (2008)
49. Strawn JR, Geracioti TD Jr. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety. (2008)
50. Casada JH, Roache JD. Behavioral inhibition and activation in posttraumatic stress disorder. J Nerv Ment Dis. (2005)
51. Swann AC, et al. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol Psychiatry. (2005)
52. Sun H, et al. Yohimbine increases impulsivity through activation of cAMP response element binding in the orbitofrontal cortex. Biol Psychiatry. (2010)
53. Shamloul R. Natural aphrodisiacs. J Sex Med. (2010)
54. Double Blind Trial of Yohimbine Hydrochloride in the Treatment of Erection Inadequacy.
55. Morales A, et al. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial. J Urol. (1987)
56. Mann K, et al. Effects of yohimbine on sexual experiences and nocturnal penile tumescence and rigidity in erectile dysfunction. Arch Sex Behav. (1996)
57. Reid K, et al. Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet. (1987)
58. Vogt HJ, et al. Double-blind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res. (1997)
59. Susset JG, et al. Effect of yohimbine hydrochloride on erectile impotence: a double-blind study. J Urol. (1989)
60. Rowland DL, Kallan K, Slob AK. Yohimbine, erectile capacity, and sexual response in men. Arch Sex Behav. (1997)
61. Kernohan AF, et al. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J Clin Pharmacol. (2005)
62. Lebret T, et al. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol. (2002)
63. Carmen GY, Víctor SM. Signalling mechanisms regulating lipolysis. Cell Signal. (2006)
64. Liu CY, Boyer JL, Mills SE. Acute effects of beta-adrenergic agonists on porcine adipocyte metabolism in vitro. J Anim Sci. (1989)
65. Lafontan M, et al. Alpha-2 adrenoceptors in lipolysis: alpha 2 antagonists and lipid-mobilizing strategies. Am J Clin Nutr. (1992)
66. Doxey JC, et al. Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine. Naunyn Schmiedebergs Arch Pharmacol. (1984)
67. Lalchandani SG, et al. Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype. J Pharmacol Exp Ther. (2002)
68. MacDonald E, Kobilka BK, Scheinin M. Gene targeting–homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci. (1997)
69. Tan S, Curtis-Prior PB. Comparative effects of RX 781094, mianserin, yohimbine, rauwolscine and prazosin in reversing clonidine inhibition of MIX-stimulated lipolysis in hamster isolated white fat cells. Pharmacol Res Commun. (1984)
70. Reiner S, et al. Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem. (2010)
71. Greenway FL, Bray GA, Heber D. Topical fat reduction. Obes Res. (1995)
72. Greenway FL, Bray GA. Regional fat loss from the thigh in obese women after adrenergic modulation. Clin Ther. (1987)
73. Pedersen SB, et al. Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution. J Clin Endocrinol Metab. (2004)
74. Keller U, Weiss M, Stauffacher W. Contribution of alpha- and beta-receptors to ketogenic and lipolytic effects of norepinephrine in humans. Diabetes. (1989)
75. Galitzky J, et al. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. (1988)
76. McCarty MF. Pre-exercise administration of yohimbine may enhance the efficacy of exercise training as a fat loss strategy by boosting lipolysis. Med Hypotheses. (2002)
77. Ito K, et al. Adrenoceptor antagonists, but not guanethidine, reduce glucopenia-induced glucagon secretion from perfused rat pancreas. Diabetes Res Clin Pract. (1995)
78. Ribes G, et al. Involvement of a central nervous pathway in yohimbine-induced insulin secretion. Eur J Pharmacol. (1989)
79. Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. (2006)
80. Sax L. Yohimbine does not affect fat distribution in men. Int J Obes. (1991)
81. Biaggioni I, Robertson RM, Robertson D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol. (1994)
82. Shibao C, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. (2010)
83. Sandberg M, et al. The α2-Adrenoceptor Antagonist Yohimbine Normalizes Increased Islet Blood Flow in GK Rats: A Model of Type 2 Diabetes. Horm Metab Res. (2012)
84. Adeghate E, Ponery AS, Wahab A. Effect of electrical field stimulation on insulin and glucagon secretion from the pancreas of normal and diabetic rats. Horm Metab Res. (2001)
85. Guay AT, et al. Yohimbine treatment of organic erectile dysfunction in a dose-escalation trial. Int J Impot Res. (2002)
86. Cuneo RC, et al. Effects of alpha-2 adrenoreceptor blockade by yohimbine on the hormonal response to hypoglycaemic stress in normal man. Horm Metab Res. (1989)
87. Krystal JH, et al. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am J Psychiatry. (1996)
88. McDougle CJ, et al. Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine. Psychopharmacology (Berl). (1995)
89. Mattila M, Seppala T, Mattila MJ. Anxiogenic effect of yohimbine in healthy subjects: comparison with caffeine and antagonism by clonidine and diazepam. Int Clin Psychopharmacol. (1988)
90. Senbel AM, Mostafa T. Yohimbine enhances the effect of sildenafil on erectile process in rats. Int J Impot Res. (2008)
91. Jordan J, Sharma AM. Potential for sibutramine-yohimbine interaction. Lancet. (2003)
92. Waluga M, et al. Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women. Clin Physiol. (1998)
93. Schuckit MA. Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry. (1984)
94. Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother. (2010)
95. Linden CH, Vellman WP, Rumack B. Yohimbine: a new street drug. Ann Emerg Med. (1985)
96. HOLMBERG G, GERSHON S. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacologia. (1961)
97. Cohen PA, et al. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal. (2015)
98. Giampreti A, et al. Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). (2009)